| Trial ID: | L4312 |
| Source ID: | NCT00792935
|
| Associated Drug: |
Mk-0941
|
| Title: |
A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00792935/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MK-0941|DRUG: Glimepiride|DRUG: Metformin
|
| Outcome Measures: |
Primary: Change From Baseline to Week 6 in 24-hour Weighted Mean Glucose, Weighted Mean Glucose (WMG) is a measure of the amount of glucose in the blood over a period of 24 hours. The WMG was derived from multiple glucose values collected during both fasting and post-meal periods. The "weighted" mean was used to avoid over-representation of post-meal glucose values., Baseline and Week 6|Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic), Hypoglycemic episodes are defined as either a fingerstick glucose measurement of ≤70 mg/dL \[3.9 mmol/L\] with or without symptoms or symptomatic hypoglycemia., Baseline to Week 6 |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
143
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-01
|
| Completion Date: |
2010-02
|
| Results First Posted: |
2012-10-03
|
| Last Update Posted: |
2015-12-17
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00792935
|
